Showing results (21-30 of 81) with videos related to
Sort By:
Pageof 9
Future Oncology (London, England)|December 5, 2014
Risk factors associated with hypersensitivity reactions to cetuximab: anti-cetuximab IgE detection as screening testBenoît Dupont, Delphine Mariotte, Bénédicte Clarisse, et al.Medicine|February 4, 2020
Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinomaOlivier Bylicki, Florian Guisier, Isabelle Monnet, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Weekly paclitaxel combined with monthly carboplatin in elderly patients with advanced non-small cell lung cancer: a multicenter phase II studyJean-Louis Pujol, Bernard Milleron, Olivier Molinier, et al.Journal of the American Academy of Dermatology|March 8, 2016
Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trialGaël Deplanque, Radj Gervais, Alain Vergnenegre, et al.Current Oncology (Toronto, Ont.)|December 13, 2021
Contribution of the Idylla<sup>TM</sup> System to Improving the Therapeutic Care of Patients with NSCLC through Early Screening of <i>EGFR</i> MutationsConstance Petiteau, Gwladys Robinet-Zimmermann, Adèle Riot, et al.La Revue Du Praticien|February 17, 2012
[Management of adverse effects of targeted therapy toxicities in oncology]Elodie Coquan, Patrick Henri, Sixtine de Raucourt, et al.Mabs|June 10, 2011
Anti-cetuximab IgE ELISA for identification of patients at a high risk of cetuximab-induced anaphylaxisDelphine Mariotte, Benoît Dupont, Radj Gervais, et al.Lung Cancer (Amsterdam, Netherlands)|March 23, 2020
Encephalitis related to immunotherapy for lung cancer: Analysis of a multicenter cohortMateo Sanchis-Borja, Charles Ricordel, Anne Marie Chiappa, et al.Oncotarget|March 2, 2018
Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study)Romain Corre, Radj Gervais, Florian Guisier, et al.Cancer Medicine|October 13, 2018
Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: A multicentric retrospective study from the GFPCPaul Lesueur, Alexandre Escande, Juliette Thariat, et al.Pageof 9